Detalles de la búsqueda
1.
Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations.
Int J Mol Sci
; 22(23)2021 Nov 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-34884672
2.
Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer.
Oncologist
; 21(5): 535-6, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27091421
3.
A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma.
JHEP Rep
; 6(4): 101021, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38617599
4.
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
Eur J Cancer
; 196: 113458, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38039779
5.
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Oncoimmunology
; 13(1): 2290787, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38170160
6.
Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence.
Cancers (Basel)
; 14(4)2022 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35205721
7.
Thyroid function impairment after chemo-immunotherapy for advanced NSCLC: a single institutional retrospective report.
Immunotherapy
; 2022 Apr 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35416048
8.
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.
J Exp Clin Cancer Res
; 41(1): 189, 2022 Jun 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35655320
9.
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
J Immunother Cancer
; 10(2)2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35217575
10.
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature.
Cancers (Basel)
; 13(19)2021 Sep 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34638377
11.
Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study.
Eur J Cancer
; 151: 49-62, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33964572
12.
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer.
Clin Cancer Res
; 27(2): 418-428, 2021 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32887722
13.
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion.
Cytotherapy
; 12(4): 466-77, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20353309
14.
Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it!
Eur J Cancer
; 133: 29-32, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32434108
15.
Treating cancer with immunotherapy in HIV-positive patients: A challenging reality.
Crit Rev Oncol Hematol
; 145: 102836, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31918216
16.
Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study.
J Thorac Oncol
; 15(3): 392-403, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31634667
17.
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies.
Breast Care (Basel)
; 15(1): 30-37, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32231495
18.
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
Oncotarget
; 9(94): 36720-36721, 2018 11 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-30613355
19.
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
Oncotarget
; 9(77): 34639-34640, 2018 10 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30349655
20.
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
Oncotarget
; 9(61): 31877-31887, 2018 08 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30159129